Homburger advised ADC Therapeutics on the amendment of the financing agreement with HealthCare Royalty
On February 23, 2026, ADC Therapeutics SA (NYSE: ADCT) announced that it had amended its royalty purchase agreement with entities managed by HealthCare Royalty.
Homburger advised Raiffeisen Schweiz Genossenschaft on issuance of CHF 465 m State Treasury Notes by the State of North Rhine-Westphalia under its Debt Issuance Programme
On February 18, 2026, the State of North Rhine-Westphalia successfully completed its issuance of (i) CHF 100 m in aggregate principal amount of 0.3675 per cent.
Homburger advised Zurich Insurance Group Ltd on the placement of 7,090,909 newly issued shares through an accelerated bookbuilding process, raising gross proceeds of CHF 3.9 bn
On March 2, 2026, Zurich Insurance Group Ltd (SIX: ZURN) announced the launch of an accelerated bookbuilding offering, which led to the successful placement of 7,090,909 newly issued shares at an offer price of CHF 550 per offered share, raising aggregate gross proceeds of approximately CHF 3.9 bn. Zurich intends to use the net proceeds …
Homburger advised Zurich Insurance Company Ltd in connection with new debt facilities entered into in relation to Zurich Insurance Group Ltd’s offer for Beazley plc
On March 2, 2026, Zurich Insurance Group Ltd (SIX: ZURN) announced its recommended all-cash offer for the entire issued and to be issued share capital of Beazley plc (Beazley). The transaction combines two highly complementary businesses, accelerating Zurich’s strategy to create the global leader in Specialty insurance.
Homburger advised UBS Switzerland AG on the issuance of EUR 1.5 bn aggregate amount Fixed Rate Covered Bonds
On February 18, 2026, UBS Switzerland AG successfully completed its issuance of EUR 750 m 2.5595 per cent.
Homburger advises Solabia Développement S.A.S. on its acquisition of the Mibelle Biochemistry Business from Persán
On February 19, 2026, Solabia Group announced that it has entered into an agreement to acquire the Mibelle Biochemistry Business from Persán, a multinational European market leader in home and personal care. The Mibelle Biochemistry Business, part of the Mibelle Group, is a Swiss innovator specializing in the development and production of high‑performance active ingredients …
Homburger advised UBS Group AG on its issuance of AUD 1 bn Tier 1 Capital Notes with an equity conversion feature
On February 13, 2026, UBS Group AG successfully completed its offering of AUD 1 bn in aggregate principal amount of 7.125 per cent. Tier 1 Capital Notes.
Homburger advised UBS Group AG on its issuance of USD 5.25 bn Callable Senior Notes under its Senior Debt Programme
On February 10, 2026, UBS Group AG successfully completed its issuance of (i) USD 2 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due April 2030, (ii) USD 1.5 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due August 2037, (iii) USD 1.25 bn in aggregate principal amount of Fixed Rate/Floating Rate Callable Senior Notes due August …
Homburger advises Alphabet on its issuance of CHF 3.055 bn in Inaugural Five-tranche CHF Offering
On 10 February 2026, Alphabet Inc., the parent company of Google LLC, successfully placed bonds in Switzerland in the aggregate amount of CHF 3.055 bn. The CHF offering was comprised of CHF 905 m aggregate principal amount of 0.4270% senior notes due 2029, CHF 700 m aggregate principal amount of 0.8900% senior notes due 2032, …
Homburger advises Transocean in its acquisition of Valaris, creating combined company with value of USD 17 bn
Homburger is advising Transocean Ltd (NYSE: RIG), a leading international provider of offshore contract drilling services for oil and gas wells, on Swiss law matters in connection with its pending acquisition of Valaris Limited (NYSE: VAL), an industry leader in offshore drilling services across all water depths and geographies. On February 9, 2026, Transocean and …